A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC).

Trial Profile

A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs EDP 494 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept
  • Sponsors Enanta Pharmaceuticals
  • Most Recent Events

    • 06 Jan 2017 Status changed from recruiting to discontinued, as according to Enanta Pharmaceuticals media release the company has decided to stop further development of EDP-494 and to focus its efforts on its wholly-owned programs in NASH/PBC, RSV and HBV.
    • 03 Oct 2016 According to Enanta Pharmaceuticals media release, data will be presented at Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Nov 2016.
    • 04 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top